Hong Hye Ran, Roh Jong-Lyel, Cho Kyung-Ja, Choi Seung-Ho, Nam Soon Yuhl, Kim Sang Yoon
Departments of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
J Surg Oncol. 2015 May;111(6):784-9. doi: 10.1002/jso.23874. Epub 2015 Jan 16.
To investigate the role of lymph node density (LND) as an independent prognostic factor in high-grade salivary gland cancers.
All 87 patients with high-grade salivary gland cancers underwent curative surgery combined with neck dissection and most of them received postoperative radiotherapy or chemoradiotherapy. LND was calculated as the ratio of positive lymph nodes to total lymph nodes harvested. Clinicopathologic variables associated with cancer-specific survival (CSS) and overall survival (OS) were identified by univariate and multivariate analyses using the Cox-proportional hazards model.
Salivary duct carcinoma was the most common tumor (54%), followed by carcinoma ex pleomorphic adenoma (22%), and others. The 5-year CSS and OS were 50.9% and 49.6%, respectively, during a median follow-up of 61 months. In univariate analysis, tumor site, pathologic nodal stage, overall tumor-node-metastasis (TNM) stage, primary tumor size > 3 cm, lymphovascular invasion, perineural invasion, extranodal extension, number of metastatic lymph nodes, and LND > 4.0 were significant prognostic factors for CSS and OS (P < 0.05 each). Tumor site, perineural invasion, and LND were independent prognostic factors for both CSS and OS in multivariate analysis (P < 0.01).
Our findings support the prognostic value of LND for high-grade salivary gland cancers.
探讨淋巴结密度(LND)作为高级别涎腺癌独立预后因素的作用。
87例高级别涎腺癌患者均接受了根治性手术联合颈部淋巴结清扫术,且大多数患者接受了术后放疗或放化疗。LND计算为阳性淋巴结数与所切除淋巴结总数的比值。采用Cox比例风险模型,通过单因素和多因素分析确定与癌症特异性生存(CSS)和总生存(OS)相关的临床病理变量。
涎腺导管癌是最常见的肿瘤(54%),其次是多形性腺瘤癌变(22%),以及其他类型。在中位随访61个月期间,5年CSS和OS分别为50.9%和49.6%。单因素分析中,肿瘤部位、病理淋巴结分期、总体肿瘤-淋巴结-转移(TNM)分期、原发肿瘤大小>3 cm、脉管侵犯、神经侵犯、结外扩展、转移淋巴结数目以及LND>4.0是CSS和OS的显著预后因素(各P<0.05)。多因素分析中,肿瘤部位、神经侵犯和LND是CSS和OS的独立预后因素(P<0.01)。
我们的研究结果支持LND对高级别涎腺癌的预后价值。